Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer
Source abstract
Abstract
Recently, interleukin (IL)-33 has been closely associated with a variety of clinical cancers. IL-33 presents both protumorigenic, and less frequently, antitumorigenic functions depending on disease conditions. IL-33 signaling appears to be a possible target for the treatment of applicable tumor diseases. This study aimed to develop an effective approach to intervene in IL-33 functioning in tumors and reveal the immunotherapeutic potential of anti-IL-33 active immunization. Recombinant truncated hepatitis B virus core antigen (HBcAg), presenting mature IL-33 molecules on the surface of virus-like particles (VLPs), was prepared and used to immunize BALB/c mice in a model of murine 4T1 breast cancer. The immunization was performed through either a preventive or therapeutic strategy in two separate studies. Anti-IL-33 immunization with VLPs elicited a persistent and highly titrated specific antibody response and significantly suppressed orthotopic tumor growth in the preventive study and lung metastasis in both studies. The underlying mechanisms might include promoting tumor-specific Th1 and CTL-mediated cellular responses and the expression of the effector molecule interferon-γ (IFN-γ), suppressing T-helper type 2 (Th2) responses, and significantly reducing the infiltration of immunosuppressive Treg (regulatory T) cells and myeloid-derived suppressor cells (MDSCs) into tumor tissues in the immunized mice. In conclusion, anti-IL-33 active immunization employing recombinant VLPs as an antigen delivery platform effectively modified the tumor microenvironment and promoted antitumor immunity, indicating the potential of this approach as a new and promising immunotherapeutic strategy for the treatment of cancers where IL-33 plays a definite protumorigenic role. STATEMENT OF SIGNIFICANCE: Interleukin (IL)-33 is closely associated with a variety of clinical cancers. IL-33 signaling appears to be a possible target for the treatment of applicable tumor diseases. Recombinant truncated hepatitis B virus core antigen (HBcAg), presenting mature IL-33 molecules on the surface of virus-like particles (VLPs), was prepared and used to immunize BALB/c mice in a model of murine 4T1 breast cancer. The immunization was performed through either a preventive or therapeutic strategy in two separate studies. Anti-IL-33 immunization with VLPs elicited a persistent and highly titrated specific antibody response and significantly suppressed orthotopic tumor growth and lung metastasis in both studies. Furthermore, anti-IL-33 active immunization employing recombinant VLPs as an antigen delivery platform effectively modified the tumor microenvironment and promoted antitumor immunity, indicating its potential as a new and promising immunotherapeutic strategy for the treatment of cancers where IL-33 plays a definite protumorigenic role.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: IL-33, ST2, and ILC Pathways · Immune Cell Function and Interaction · Eosinophilic Esophagitis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Serum interleukin-33 levels in patients with gastric cancer10.1007/s10620-011-1760-5 ↗
2. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma10.1593/tlo.12418 ↗
3. Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue10.1016/j.anl.2014.08.007 ↗
4. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation10.1172/JCI73742 ↗
5. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer10.7314/APJCP.2013.14.4.2563 ↗
6. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of cot activity10.1038/onc.2014.418 ↗
7. Interleukin-33 expression indicates a favorable prognosis in malignant salivary gland tumors10.1177/1066896916633856 ↗
8. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating Erk and Jnk signaling pathways10.1016/j.molonc.2015.06.004 ↗
9. Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma10.1080/00207454.2016.1175441 ↗
10. IL-33 signaling fuels outgrowth and metastasis of human lung cancer10.1016/j.bbrc.2016.09.081 ↗
11. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications10.1177/030006051204000504 ↗
12. IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma10.1007/s13277-016-4879-3 ↗
13. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines10.1016/j.immuni.2005.09.015 ↗
14. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex10.4049/jimmunol.0803067 ↗
15. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells10.1073/pnas.0705939104 ↗
16. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-3310.1182/blood-2008-05-157818 ↗
17. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity10.1038/nature08900 ↗
18. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity10.1038/ni.2045 ↗
19. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation10.4049/jimmunol.0901575 ↗
20. IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells10.4049/jimmunol.181.1.62 ↗
21. IL-33-activated dendritic cells induce an atypical TH2-type response10.1016/j.jaci.2009.02.026 ↗
22. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells10.1002/ijc.28481 ↗
23. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells10.1080/2162402X.2015.1063772 ↗
24. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms10.1172/JCI77347 ↗
25. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer10.1016/j.bbrc.2014.09.106 ↗
26. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway10.1007/s10620-014-3463-1 ↗
27. IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment10.1158/0008-5472.CAN-16-1602 ↗
28. IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model10.18632/oncotarget.19786 ↗
29. Virus-like particles presenting interleukin-33 molecules: immunization characteristics and potentials of blockingIL-33/ST2 pathway in allergic airway inflammation10.4161/hv.29425 ↗
30. Development of an interleukin (IL)-33 sandwich Elisa kit specific for mature IL-3310.1080/15321819.2016.1179645 ↗
31. IL-33 in T cell differentiation, function, and immune homeostasis10.1016/j.it.2016.03.007 ↗
32. IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice10.1038/icb.2016.72 ↗
33. IL-33 increases ST2(+) Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner10.1080/2162402X.2018.1527497 ↗
34. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome10.1126/science.1129139 ↗
35. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses10.4049/jimmunol.1000749 ↗
36. Immunosuppressive networks in the tumour environment and their therapeutic relevance10.1038/nrc1586 ↗
37. Regulatory T cells, tumour immunity and immunotherapy10.1038/nri1806 ↗
38. Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis10.1155/2014/686879 ↗
39. The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages10.1038/ncomms11385 ↗
40. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy10.1007/s00109-016-1397-0 ↗
41. G.J. Pearce, I.C. Chikanza, Targeting tumour necrosis factor in the treatment of rheumatoid arthritis, Biodrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy15(3) (2001) 139–49.10.2165/00063030-200115030-00001 ↗
42. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment10.2174/156800911793743583 ↗
43. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer10.1200/JCO.2007.11.5980 ↗
44. Therapeutic vaccines for cancer: an overview of clinical trials10.1038/nrclinonc.2014.111 ↗
45. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment10.1038/ncomms13589 ↗
46. IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population10.1038/ncomms14919 ↗
47. Disease-associated functions of IL-33: the new kid in the IL-1 family10.1038/nri2692 ↗
48. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice10.1016/j.canlet.2013.03.002 ↗
49. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-3310.1038/srep30555 ↗
50. Examining IL-33 expression in the cervix of HPV-infected patients: a preliminary study comparing IL-33 levels in different stages of disease and analyzing its potential association with IFN-gamma10.1007/s12032-014-0143-0 ↗
51. Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model10.1016/j.vaccine.2015.03.086 ↗
52. The role of IL-33-Dependent inflammation in the tumor microenvironment
53. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells10.4049/jimmunol.1401344 ↗